TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, reports that its ...
A lack of diversity among research participants can impact the generalizability of study results, create differential access to the benefits of research innovations, and impede the development of ...
WASHINGTON – When conducting research involving the testing of human biospecimens, investigators and their institutions should routinely consider whether and how to return individual research results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback